Small molecule-drug conjugates (SMDCs) are increasingly being considered as an alternative to antibody-drug conjugates (ADCs) for the selective delivery of anticancer agents to the tumor site, sparing normal tissues. Carbonic anhydrase IX (CAIX) is a membrane-bound enzyme, which is over-expressed in the majority of renal cell carcinomas and which can be efficiently targeted in vivo, using charged derivatives of acetazolamide, a small heteroaromatic sulfonamide. Here, we show that SMDC products, obtained by the coupling of acetazolamide with monomethyl auristatin E (MMAE) using dipeptide linkers, display a potent anti-tumoral activity in mice bearing xenografted SKRC-52 renal cell carcinomas. A comparative evaluation of four dipeptides revealed that SMDCs featuring valine-citrulline and valine-alanine linkers exhibited greater serum stability and superior therapeutic activity, compared to the counterparts with valine-lysine or valine-arginine linkers. The most active products substantially inhibited tumor growth over a prolonged period of time, in a tumor model for which sunitinib and sorafenib do not display therapeutic activity. However, complete tumor eradication was not possible even after ten intravenous injection. Macroscopic near-infrared imaging procedures confirmed that ligands had not lost the ability to selectively localize at the tumor site at the end of therapy and that the neoplastic masses continued to express CAIX. The findings are of mechanistic and of therapeutic significance, since CAIX is a noninternalizing membrane-associated antigen, which can be considered for targeted drug delivery applications in kidney cancer patients.
Introduction
The majority of low molecular weight drugs, commonly used for cancer chemotherapy, do not preferentially localize to solid tumors in mice [1, 2] and patients [3] . This unfavorable pharmacokinetic behavior may lead to undesired toxicity to normal organs and may limit the dose escalation to therapeutically active regimens. In order to improve the therapeutic activity of anticancer chemotherapy, the coupling of cytotoxic agents to monoclonal antibodies has been proposed and experimentally explored, at the preclinical and clinical level [4] [5] [6] [7] . Several monoclonal antibody-drug conjugates (ADCs) have exhibited promising therapeutic results in mouse models of cancer and two products (Adcetris™ and Kadcyla™) have gained marketing authorization for the treatment of certain malignancies in patients. However, the clinical performance of ADC products is often limited by the slow extravasation of the antibody molecule [8] , suboptimal in vivo selectivity [9] and premature drug release [10] [11] [12] , which may contribute to undesired toxicities and limit therapeutic efficacy.
Small molecule-drug conjugates (SMDCs), capable of selective localization at the tumor site, have been proposed as an alternative to ADCs [13] . Small organic ligands, specific to accessible tumor-associated antigens, extravasate and diffuse into tissues more rapidly than antibodies [14, 15] , These pharmacokinetic characteristics may lead to favorable tumor:blood and tumor:organ ratios at early time points (e.g., few hours) after intravenous administration [16] . Small molecule ligands have been used for the selective in vivo targeting of tumors expressing the folate receptor [17, 18] , prostate-specific membrane antigen [16, 19] and somatostatin receptors [20] . A number of SMDC products are currently being investigated in clinical trials [21] Carbonic anhydrase IX (CAIX) is a membrane-bound homodimeric enzyme, which is undetectable in most normal adult tissues [22] . CAIX can be found in certain gastro-intestinal structures (e.g., stomach, duodenum and gallbladder) [23] , albeit in a catalytically-inactive form [24] , and in hypoxic tissues [25] . Interestingly, CAIX is also strongly expressed in the majority of kidney cancers, as a result of von Hippel-Lindau mutations and the in vivo ligand-based targeting of this enzyme is more efficient in tumors, compared to normal organs [26] . Moreover, the antigen has been reported to be abundant in a subset of patients with different cancers (i.e., lung, colorectum, stomach, pancreas, breast, cervix, bladder, ovaries, brain, head and neck and oral cavity [27] ) with an over-expression at the growing front of the tumor [28] .
Even though CAIX has previously been claimed to be an internalizing antigen and has been considered for industrial ADC product development activities [29] , our lab has experimentally shown that the protein remains membrane-bound and does not efficiently internalize upon small-ligand binding [30, 31] .
Acetazolamide is a small heteroaromatic sulfonamide, which binds to various carbonic anhydrases with high affinity. Derivatives of acetazolamide containing multiple charges do not efficiently cross the cell membrane and are restricted for binding to membrane-accessible carbonic anhydrases (i.e., CAIX, but also potentially CAIV and CAXII). We have previously shown that certain acetazolamide derivatives selectively localize to renal cell carcinomas in vivo [30] [31] [32] [33] and that those ligands can be used for the selective delivery of highly cytotoxic maytansinoids (e.g., DM1) to kidney tumors. Interestingly, the use of disulfide linkers for the coupling of DM1 to acetazolamide allows an efficient and selective drug release at the tumor site, where dying cells release large amounts of glutathione and other reducing agents. Indeed, disulfide linkers have been proposed as selective modules for drugs release also with antibody-drug conjugates [34, 35] and with polymer-drug conjugates [36] .
In this article, we describe the synthesis and characterization of four SMDCs, in which the acetazolamide moiety was coupled to monomethyl auristatin E (MMAE, the payload in Adcetris™) via cleavable linkers, featuring four different dipeptide structures. We observed that valine-citrulline and valine-alanine linkers were more stable in serum, compared to the charged valine-lysine and valine-arginine structures. Interestingly, the two most stable SMDCs were also the most therapeutically active products, when tested in mice with xenografted SKRC-52 tumors. These findings are of potential therapeutic significance, as the CAIX targeting agents could be considered for applications in humans. Furthermore, our data indicate that potent therapeutic activity can be achieved in vivo, using non-internalizing ligands and linkers, which had previously been postulated to be processed only in intracellular compartments, by cathepsin B cleavage [37, 38] .
Materials and methods

General remarks
Compound 1 [30] and Fmoc-Lys(Mtt)-PABOH [39] were prepared according to literature procedures and their analytical data were in agreement with those already published. MC-ValCit-PABC-MMAE was purchased from Levena Biopharma (No. 9 Weidi Road, Qixia District, Nanjing, 210,046, China). Maleimidoethyl-IRDye680RD was purchased from LI-COR Biosciences (4647 Superior Street Lincoln, Nebraska USA 68504-5000). The synthetic procedures for the preparation of the ValAla, ValLys, ValArg analogues, of the final SMDCs 2-5 and of the near-infrared dye derivative 6 are included in the Supplementary information, along with NMR/HPLC-MS data and the statistical analysis of the in vivo experiments.
General procedure for acetazolamide-drug conjugation
Compound 1 (4 eq) was dissolved in phosphate buffered saline (PBS; 50 mM phosphate, 100 mM NaCl, pH 7.4) and a solution of MC-linker-PABC-MMAE (1 eq) in DMF was added. The mixtures were stirred at room temperature until completion (monitored by HPLC-MS) and the solvents were removed under vacuum. The conjugates were purified through RP-HPLC and lyophilized. The purity (N 95%) of the final compounds was detected by analytical HPLC-MS.
Linker stability assays
Compounds 1-4 were incubated at 37°C in a shaking incubator as PBS solutions (pH 7.4; 100 μg/ml). Aliquots (200 μl) were collected at subsequent time points (0, 15 min, 1 h, 3 h, 6 h, 24 h, 96 h) and frozen at −20°C. The samples were analyzed in triplicate by LC-MS. Peaks relative to the pro-drugs were integrated and area values from samples at different time points were used to obtain fractions of intact test compounds. Fraction values were plotted to obtain stability profiles showed in Fig. 2 .
Analogously, test compounds were dissolved in DMSO (10 μl), diluted with freshly thawed mouse serum (Invitrogen) (100 μg/ml) and incubated at 37°C in a shaking incubator. Aliquots (100 μl) were collected at subsequent time points (0, 20 min, 1 h, 3 h, 6 h, 24 h and 48 h) and frozen at − 20°C. Samples were thawed and diluted with four volumes of MeOH (400 μl). After vigorous vortex agitation for 1 min, the protein precipitate was spun down and 400 μl of the supernatant was lyophilized overnight. The resulting solid material was re-dissolved in 200 μl of water, filtered and analyzed as described above.
Cell cultures
The human renal cell carcinoma cell line SKRC-52 was kindly provided by Professor E. Oosterwijk (Radbound University Nijmegen Medical Centre, Nijmegen, The Netherlands) and tested for CAIX expression by immunofluorescence. No further authentication was performed. SKRC-52 were maintained in RPMI medium (Invitrogen) supplemented with fetal calf serum (10%, FCS, Invitrogen) and Antibiotic-Antimycotic (1%, AA, Invitrogen) at 37°C and 5% CO 2 . For passaging, cells were detached using Trypsin-EDTA 0.05% (Invitrogen) when reaching 90% confluence and re-seeded at a dilution of 1:6.
In vitro cytotoxicity assay
SKRC-52 cells were seeded in 96-well plates in RPMI added with 10% FCS (100 μl) at a density of 5000 cells per well and allowed to grow for 24 h. The medium was replaced with medium containing different concentrations of test substance (1:3 dilution steps) and plates were incubated at 37°C and 5% CO 2 . After 72 h the medium was replaced by a solution of MTS cell viability dye (20 μl, Promega) in 150 μl of medium. Plates were incubated for 2 h under culture conditions and the absorbance at 490 nm measured on a Spectra Max Paradigm multimode plate reader (Molecular Devices). Experiments were performed in triplicate and average cell viability calculated as measured background corrected absorbance divided by the absorbance of untreated control wells. IC 50 values were determined by fitting data to the four-parameter logistic equation, using a Prism 6 software (GraphPad Software) for data analysis.
Animal studies
All animal experiments were conducted in accordance with Swiss animal welfare laws and regulations under the license number 27/2015 granted by the Veterinäramt des Kantons Zürich. 
Therapy Experiments
SKRC-52 xenografted tumors were implanted into female Balb/c nu/ nu mice (Janvier) as described above, and allowed to grow for two weeks to an average volume of 0.1 ml. Mice were randomly assigned into therapy groups of 4 animals and treatment started by injecting a solution of the targeted drugs or vehicle (PBS containing 1% of DMSO) intravenously (tail vein) at the dose of 250 nmol/kg, following the schedule depicted by the arrows in the corresponding Figure. Compounds 2-5 were injected as solutions in sterile PBS containing 1% DMSO. Animals were weighed and tumor sizes were measured daily with an electronic caliper. The tumor volume was calculated according to the formula (long side) × (short side) × (short side) × 0.5. Animals were sacrificed when the termination criteria were reached. Prism 6 software (GraphPad Software) was used for data analysis (regular two-way ANOVA with the Bonferroni test).
IVIS imaging
Female Balb/c nude mice bearing subcutaneous SKRC-52 tumors were injected intravenously with compound 6, containing the near infrared dye moiety IRDye680RD (LI-COR Biosciences) (250 nmol/kg), dissolved in sterile PBS (100 μl). Mice were anesthetized with isoflurane and fluorescence images acquired on an IVIS Spectrum imaging system (Xenogen, exposure 1 s, binning factor 8, excitation at 675 nm, emission filter at 720 nm, f number 2, field of view 13.1). Images were taken before the injection and after 30 min, 1 h and 3 h. Food and water was given ad libitum during that period.
Immunofluorescence studies
SKRC-52 tumors excised from the mice after therapy study were embedded in OCT medium (Thermo Scientific), and cryostat sections (10 μm) were cut. Slides were stored at −80°C overnight, fixed with acetone and stained using the following antibodies: mouse anti-human CAIX GT12 (Thermo Scientific), to detect the antigen, and rat antimouse CD31 (BD Biosciences) to detect endothelial cells. Nuclear staining was performed with DAPI. Anti-mouse IgG-AlexaFluor488 (Molecular Probes by Life Technologies) and anti-rat IgG-AlexaFluor594 (Molecular Probes by Life Technologies) were then used as secondary antibodies for microscopic detection. Fig. 1 ), was then coupled to the MMAE-dipeptide-maleimido derivative, yielding products 2-5. These compounds featured valine-alanine, valine-lysine, valine-arginine or valine-citrulline dipeptide structures as cleavable moieties, respectively, which can subsequently trigger the release of the MMAE cytotoxic moiety [ Fig. 1 ]. Compound 1 was prepared by solid phase synthesis, installing the acetazolamide moiety onto the Asp-Arg-Asp-Cys tetrapeptide linker by a copper-catalyzed azide-alkyne cycloaddition "on resin" [Fig. 1 ].
The stability of the acetazolamide-MMAE conjugates 2-5, bearing different cleavable dipeptide sequences, was analyzed by LC/MS. The methodology detected the amounts of intact compounds at various time points, upon incubation at 37°C in either phosphate-buffered saline (PBS) or mouse serum [ Fig. 2] . While no degradation of the tested conjugates was observed in PBS (t 1/2 N 96 h in at 37°C), compounds 2-5 exhibited various degrees of chemical stability in mouse serum at 37°C. Since free MMAE was detected as end product in LC/MS analysis, in parallel to the progressive disappearance of the conjugates, the stability profiles of Fig. 2 can be related to the differential susceptibility to proteolytic cleavage of the corresponding dipeptide linkers. In particular, conjugates 2 and 5 (i.e., featuring the ValAla and ValCit linkers, respectively) showed the highest stability (t 1/2 = 23 h and 11.2 h), compared to the more labile compounds 3 (ValLys; t 1/2 = 8.2 h) and 4 (ValArg; t 1/2 = 1.8 h).
These data are in agreement with previous publications [40, 41] , which reported the lower stability of linkers featuring protonable side chains (e.g., Arg, Lys) in serum or in the presence of proteases. Considering the rapid clearance of acetazolamide derivatives from the blood (with half-lives which are typically shorter than 15 min) [30, 33, 42] , the serum stability of compounds 2-5 is sufficient for in vivo pharmacodelivery applications, favoring a preferential tumor uptake and a slow drug release at the site of disease.
The antiproliferative activity of conjugates 2-5 was tested in vitro against CAIX-positive renal carcinoma SKRC-52 cells, using the free MMAE payload as reference compound [ Fig. 3 ]. Cells were incubated for 72 h in the presence of different concentrations of the tested compounds. Under this experimental procedure, the free MMAE drug was found to inhibit cell proliferation at sub-nanomolar concentrations (IC 50 = 0.9 nM). Only a small decrease in cytotoxic activity was observed for the pro-drugs AAZ-ValLys-MMAE (3) and AAZ-ValArg-MMAE (4), which showed IC 50 values of 1.6 nM and IC 50 = 2.1 nM, respectively. By contrast, compounds AAZ-ValAla-MMAE (2) and AAZValCit-MMAE (5) were found to be substantially less potent than the free drug in vitro (i.e., IC 50 values of 69 nM and 171 nM, respectively). This observation is in keeping with the enhanced serum stability of the ValAla and ValCit linkers, compared to ValLys and ValArg [ Fig. 2B ].
Therapy experiments
The therapeutic activity of the acetazolamide derivatives 2-5 was tested in immunodeficient Balb/c nude mice, xenografted subcutaneously with SKRC-52 [30] . Multiple intravenous injections at equivalent molar doses (250 nmol/kg) were performed following the schedule indicated in Fig. 4 . All conjugates 2-5 significantly inhibited tumor growth, compared to saline treatment (p b 0.0001) [Fig. 4A] .
The acetazolamide derivatives, featuring ValAla (2) and ValCit (5) as cleavable linkers, displayed the best antitumor efficacy (p b 0.0001). None of the study groups exhibited a body weight loss of more than 10%, which was comparable to the one observed in the saline treatment group [ Fig. 4B] . A second cycle of four injections at the same dose was administered to mice, which had enjoyed the largest tumor growth inhibition as a result of AAZ-ValAla-MMAE and AAZValCit-MMAE treatment. However, the second cycle of injections did not result in a tumor regression [ Fig. 4A ]. In order to better characterize the mechanism of resistance to drug action at late time points, mice were treated with a near-infrared fluorescent derivative of acetazolamide (compound 6) [ Fig. 5A ]. For all treatment groups, the imaging data confirmed the ability of acetazolamide to selectively target tumor lesions at the end of the therapy experiment [ Fig. 5B ]. After sacrifice of the mice, tumor sections were stained with anti-CAIX antibodies, confirming that tumor cells had not lost antigen expression 
Discussion
Patients with metastatic renal cell carcinoma (RCC) typically receive sunitinib or sorafenib as first-line treatment, but durable objective responses are rarely observed [43] . Both of these drugs fail to preferentially localize on tumor lesions [44, 45] and are poorly active in mouse models of RCC. Interestingly, sunitinib and sorafenib treatment in mice bearing SKRC52 tumors was not significantly better than saline treatment [30] , while the acetazolamide derivatives 2 and 5 exhibit a substantial and prolonged tumor regression [Fig. 4] .
In spite of their therapeutic activity and good tolerability profile, the conjugates AAZ-ValAla-MMAE (2) and AAZ-ValCit-MMAE (5) were not able to cure mice with SKRC52 tumors, when used at the maximal tolerated dose of 250 nmol/kg. This dose is compatible with an efficient ligand localization at the tumor site, as revealed by quantitative biodistribution studies with radiolabeled acetazolamide derivatives [31, 33] . The lack of sufficient therapeutic activity at later time points was not associated with loss of ligand-based targeting or of CAIX expression by tumor cells [Fig. 5 ]. The use of human tumors grafted in nude mice does not allow to study the contribution of the adaptive arm of the immune system to tumor rejection. In the future, it will be interesting to study the therapeutic activity of compounds 2 and 5 in syngeneic tumor models, expressing CAIX. Potentially, these agents could synergize with other interventional modalities, such as external beam radiation [46] or certain immunostimulatory regimens [47] in promoting tumor rejection.
Developed in the late 90s [48] , the valine-citrulline linker is one of the most broadly used dipeptide linkers in the ADC field, being included in the majority of MMAE-based ADCs in clinical studies [49] , including brentuximab vedotin [50] . Interestingly, the valine-alanine dipeptide has been used in two pyrrolobenzodiazepine (PBD)-based ADCs that are currently being evaluated in the clinic. Notably, the CD33-targeting ADC Vadastuximab Talirine (SGN-CD33A) has recently entered pivotal phase 3 CASCADE study in patients with newly diagnosed acute myeloid leukemia (AML). For all these ADC products, the proposed mechanism of action featured a selective antibody internalization into antigen-positive cells, followed by intracellular release of the payload. We have shown, however, that both ADC linkers based on disulfides or on peptide structures can efficiently liberate drug in the tumor extracellular environment, with a therapeutic benefit in rodent models of cancer [34, 35] .
Some examples of SMDC products, featuring protease-cleavable linkers (e.g., incorporating the ValCit [51, 52] and ValAla [53, 54] dipeptides) have previously been reported. Together with the uptake in healthy organs, an insufficient in vivo stability of the linker may contribute to off-target toxicities and loss of efficacy [10] [11] [12] . Our comparative evaluation of acetazolamide-peptide-conjugates indicates a correlation between linker stability and activity. Acetazolamide derivatives can achieve tumor:blood ratios N100:1 six hours after intravenous administration [31, 33] . SMDC products with a serum stability of at least few hours (t 1/2 N 10 h for valine-citrulline and valine-alanine derivatives) are thus able to preferentially localize at the cancer site, before releasing their payload in the tumor environment. The growing body of experimental evidence, documenting a preferential drug release in the extracellular tumor space using non-internalizing conjugates equipped with disulfide or peptidic linkers [30, 31, 34, 35] , indicates that sufficient amounts of reducing agents (e.g., glutathione) and of proteases (e.g., cathepsin B) are set free as a result of malignant cell death.
In order to facilitate a clinical translation of the best-performing MMAE conjugates, it will be essential to characterize the tumortargeting ability of acetazolamide derivatives in patients with metastatic kidney cancer. We have recently described an acetazolamide derivative, which can be labeled with 99m Tc and which has recently completed GMP manufacturing [31, 33] . In full analogy to monoclonal antibodies [55, 56] , Nuclear Medicine studies in patients have the potential to accompany product development activities for SMDCs.
Conclusions
Small molecule-drug conjugates, containing acetazolamide as tumor homing moiety, dipeptide-based linkers and monomethyl auristatin E as cytotoxic payload, are potently active in a mouse model of renal cell carcinoma. A comparative analysis of four dipeptide linkers (ValAla, ValLys, ValArg and ValCit) has allowed the identification of at least two acetazolamide-drug conjugates, which display sufficient stability in serum and a potent anticancer activity. The data presented in the article reinforce the concept that potent payloads can be released from non-internalizing ligands in the tumor extracellular space, when suitable linkers are used.
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